Amitriptyline's anticholinergic adverse drug reactions-A systematic multiple-indication review and meta-analysis.

Brueckle M-S, Thomas ET, Seide SE, Pilz M, Gonzalez-Gonzalez AI, Dinh TS, Gerlach FM, Harder S, Glasziou PP, Muth C (2023)
PLoS ONE 18(4): e0284168.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA 1.68 MB
Autor*in
Brueckle, Maria-Sophie; Thomas, Elizabeth T; Seide, Svenja Elisabeth; Pilz, Maximilian; Gonzalez-Gonzalez, Ana I; Dinh, Truc Sophia; Gerlach, Ferdinand M; Harder, Sebastian; Glasziou, Paul P; Muth, ChristianeUniBi
Abstract / Bemerkung
BACKGROUND: Half the US population uses drugs with anticholinergic properties. Their potential harms may outweigh their benefits. Amitriptyline is among the most frequently prescribed anticholinergic medicinal products, is used for multiple indications, and rated as strongly anticholinergic. Our objective was to explore and quantify (anticholinergic) adverse drug reactions (ADRs) in patients taking amitriptyline vs. placebo in randomized controlled trials (RCTs) involving adults and healthy individuals.; METHODS: We searched electronic databases from their inception until 09/2022, and clinical trial registries from their inception until 09/2022. We also performed manual reference searches. Two independent reviewers selected RCTs with ≥100 participants of ≥18 years, that compared amitriptyline (taken orally) versus placebo for all indications. No language restrictions were applied. One reviewer extracted study data, ADRs, and assessed study quality, which two others verified. The primary outcome was frequency of anticholinergic ADRs as a binary outcome (absolute number of patients with/without anticholinergic ADRs) in amitriptyline vs. placebo groups.; RESULTS: Twenty-three RCTs (mean dosage 5mg to 300mg amitriptyline/day) and 4217 patients (mean age 40.3 years) were included. The most frequently reported anticholinergic ADRs were dry mouth, drowsiness, somnolence, sedation, fatigue, constitutional, and unspecific anticholinergic ADRs. Random-effects meta-analyses showed anticholinergic ADRs had a higher odd's ratio for amitriptyline versus placebo (OR = 7.41; [95% CI, 4.54 to 12.12]). Non-anticholinergic ADRs were as frequent for amitriptyline as placebo. Meta-regression analysis showed anticholinergic ADRs were not dose-dependent.; DISCUSSION: The large OR in our analysis shows that ADRs indicative of anticholinergic activities can be attributed to amitriptyline. The low average age of participants in our study may limit the generalizability of the frequency of anticholinergic ADRs in older patients. A lack of dose-dependency may reflect limited reporting of the daily dosage when the ADRs occurred. The exclusion of small studies (<100 participants) decreased heterogeneity between studies, but may also have reduced our ability to detect rare events. Future studies should focus on older people, as they are more susceptible to anticholinergic ADRs.; REGISTRATION: PROSPERO: CRD42020111970. Copyright: © 2023 Brueckle et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Erscheinungsjahr
2023
Zeitschriftentitel
PLoS ONE
Band
18
Ausgabe
4
Art.-Nr.
e0284168
eISSN
1932-6203
Page URI
https://pub.uni-bielefeld.de/record/2978078

Zitieren

Brueckle M-S, Thomas ET, Seide SE, et al. Amitriptyline's anticholinergic adverse drug reactions-A systematic multiple-indication review and meta-analysis. PLoS ONE . 2023;18(4): e0284168.
Brueckle, M. - S., Thomas, E. T., Seide, S. E., Pilz, M., Gonzalez-Gonzalez, A. I., Dinh, T. S., Gerlach, F. M., et al. (2023). Amitriptyline's anticholinergic adverse drug reactions-A systematic multiple-indication review and meta-analysis. PLoS ONE , 18(4), e0284168. https://doi.org/10.1371/journal.pone.0284168
Brueckle, Maria-Sophie, Thomas, Elizabeth T, Seide, Svenja Elisabeth, Pilz, Maximilian, Gonzalez-Gonzalez, Ana I, Dinh, Truc Sophia, Gerlach, Ferdinand M, Harder, Sebastian, Glasziou, Paul P, and Muth, Christiane. 2023. “Amitriptyline's anticholinergic adverse drug reactions-A systematic multiple-indication review and meta-analysis.”. PLoS ONE 18 (4): e0284168.
Brueckle, M. - S., Thomas, E. T., Seide, S. E., Pilz, M., Gonzalez-Gonzalez, A. I., Dinh, T. S., Gerlach, F. M., Harder, S., Glasziou, P. P., and Muth, C. (2023). Amitriptyline's anticholinergic adverse drug reactions-A systematic multiple-indication review and meta-analysis. PLoS ONE 18:e0284168.
Brueckle, M.-S., et al., 2023. Amitriptyline's anticholinergic adverse drug reactions-A systematic multiple-indication review and meta-analysis. PLoS ONE , 18(4): e0284168.
M.-S. Brueckle, et al., “Amitriptyline's anticholinergic adverse drug reactions-A systematic multiple-indication review and meta-analysis.”, PLoS ONE , vol. 18, 2023, : e0284168.
Brueckle, M.-S., Thomas, E.T., Seide, S.E., Pilz, M., Gonzalez-Gonzalez, A.I., Dinh, T.S., Gerlach, F.M., Harder, S., Glasziou, P.P., Muth, C.: Amitriptyline's anticholinergic adverse drug reactions-A systematic multiple-indication review and meta-analysis. PLoS ONE . 18, : e0284168 (2023).
Brueckle, Maria-Sophie, Thomas, Elizabeth T, Seide, Svenja Elisabeth, Pilz, Maximilian, Gonzalez-Gonzalez, Ana I, Dinh, Truc Sophia, Gerlach, Ferdinand M, Harder, Sebastian, Glasziou, Paul P, and Muth, Christiane. “Amitriptyline's anticholinergic adverse drug reactions-A systematic multiple-indication review and meta-analysis.”. PLoS ONE 18.4 (2023): e0284168.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2024-01-11T12:47:51Z
MD5 Prüfsumme
2e32747a9668ec81b3dab463200c511d


Link(s) zu Volltext(en)
Access Level
OA Open Access

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 37018325
PubMed | Europe PMC

Suchen in

Google Scholar